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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to boron 
and prevention and treatment of prostate cancer (ID 221), maintenance of 
normal thyroid function (ID 222) and contribution to normal cognitive 









European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to boron and prevention and treatment of prostate cancer, maintenance of normal thyroid 
function and contribution to normal cognitive function. The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claims is boron. The Panel considers that boron 
is sufficiently characterised. 
Prevention and treatment of prostate cancer 
The claimed effect is “prostate health”. The target population is assumed to be adult males. The Panel 
notes that the references provided referred to the consumption of boron in relation to prostate cancer 
prevention and treatment.  
The Panel considers that the claim is related to the prevention and treatment of a disease, and does not 
comply with the criteria laid down in Regulation (EC) No 1924/2006. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1008, EFSA-Q-2008-1009, EFSA-Q-2008-1010, 
adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Mental/Nervous System: Jacques Rigo, Astrid Schloerscheidt, Barbara Stewart-Knox, Sean (J.J.) Strain, and Peter 
Willatts. 
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Maintenance of normal thyroid function  
The claimed effect is “thyroid health”. The target population is assumed to be the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
maintenance of normal thyroid function. The Panel considers that maintenance of normal thyroid 
function is a beneficial physiological effect. 
No human studies were provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis of the data presented the Panel concludes that a cause and effect relationship has not 
been established between the consumption of boron and maintenance of normal thyroid function. 
Contribution to normal cognitive function  
The claimed effect is “mental health”. The target population is assumed to be the general population. 
In the context of the references provided, the Panel assumes that the claimed effect refers to 
contribution to normal cognitive function. The Panel considers that contribution to normal cognitive 
function is a beneficial physiological effect. 
No human studies were provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis of the data presented the Panel concludes that a cause and effect relationship has not 
been established between the consumption of boron and contribution to normal cognitive function. 
KEY WORDS 
Boron, prostate cancer, thyroid function, cognitive function, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is boron. 
It has not been established that boron is an essential nutrient for humans. Boron occurs in foods as 
borate and boric acid, and can be measured by established methods. Daily intakes of boron from food 
and water vary from 1 to 7 mg/day, depending on geographical region and dietary patterns (Richold, 
1998). Main dietary sources are plant foods. Fruits, legumes, leafy vegetables, nuts, wine, cider and 
beer are particularly rich sources (Naghii et al., 1996). Drinking water typically contains <1 mg 
boron/L, albeit the range is large. The mean intake from water ranges from 0.2-0.6 mg/day (EFSA, 
2004). 
Boron is authorised for addition to foods (Annex I of Regulation (EC) No 1925/2006
6
 and Annex I of 
Directive 2002/46/EC
7
). This evaluation applies to boron naturally present in foods and added to 
foods. 
The Panel considers that the food constituent, boron, which is the subject of the health claims, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Prevention and treatment of prostate cancer (ID 221) 
The claimed effect is “prostate health”. The Panel assumes that the target population is adult males. 
The Panel notes that the references provided referred to the consumption of boron in relation to 
prostate cancer prevention and treatment.  
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
7  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
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The Panel considers that the claim is related to the prevention and treatment of a disease, and does not 
comply with the criteria laid down in Regulation (EC) No 1924/2006. 
2.2. Maintenance of normal thyroid function (ID 222) 
The claimed effect is “thyroid health”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
maintenance of normal thyroid function. 
The Panel considers that maintenance of normal thyroid function is a beneficial physiological effect. 
2.3. Contribution to normal cognitive function (ID 223) 
The claimed effect is “mental health”. The Panel assumes that the target population is the general 
population. 
In the context of the references provided, the Panel assumes that the claimed effect refers to 
contribution to normal cognitive function. Cognitive function includes memory, attention 
(concentration), learning, intelligence and problem solving, which are well defined constructs and 
which can be measured by validated psychometric cognitive tests. 
The Panel considers that contribution to normal cognitive function is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
3.1. Maintenance of normal thyroid function (ID 222) 
Among the references provided to substantiate the claim were two narrative reviews that discussed 
possible biological functions of boron but did not provide original data for the scientific 
substantiation of the claim. One reference was in Russian and a translation in an EU language was not 
available to the Panel. One animal study did not address endpoints related to normal thyroid function. 
The Panel considers that no conclusions can be drawn from these references for the scientific 
substantiation of the claim. 
One animal study addressed the effects of boron supplementation on thyroid hormone concentrations 
in pigs. The Panel considers that human studies are required for the substantiation of a claim, and that 
evidence provided in animal studies alone is not sufficient to predict the occurrence of an effect of 
boron consumption on the maintenance of normal thyroid function in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of boron and maintenance of normal thyroid function. 
3.2. Contribution to normal cognitive function (ID 223) 
Among the references provided was one animal study which did not address endpoints related to 
normal cognitive function. The Panel considers that no conclusions can be drawn from this reference 
for the scientific substantiation of the claim. Among the references provided were also several 
textbooks, reports from authoritative bodies and narrative reviews referring to potential biological 
functions of boron in humans. Some of these references mentioned a possible role for boron in brain 
function, and referred to the work of Penland (1994, 1998) described below.  
Boron related health claims 
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A randomised, double-blind, placebo-controlled, cross-over trial was undertaken in 13 healthy post-
menopausal women aged 50 to 78 years not receiving oestrogen-replacement therapy (Penland, 1994, 
1998). For 21 days (equilibration period), subjects received a diet supplemented with 200 mg 
magnesium and 3 mg boron/2000 kcal/day. Each subject was then given all four supplement 
combinations created by the factorial crossing of 0 (placebo) and 200 mg magnesium with 0 (placebo) 
and 3 mg boron for 42 days, each in a random order. Supplements were administered using a Latin 
square design. Two types of measure were collected. One of these measures was brain electrical 
activity, which was analysed according to frequency bands. The Panel notes that brain electrical 
frequency patterns are not established measures of cognitive function. The second type of measure 
was a selection of cognitive and psychomotor tests taken from the Cognition Psychomotor 
Assessment System battery which was developed by the author, and which was inadequately 
referenced and does not appear to have been fully validated. These data were collected during the last 
week of each 42-day period. The Panel notes that the test battery comprised 13 cognitive and 
psychomotor tests, some of which included several sub-tests, and that no adjustment for multiple 
testing was made. The Panel considers that no conclusions can be drawn from this reference for the 
scientific substantiation of the claim.  
Two other human studies were undertaken by the same laboratory in 15 healthy adults (five men, five 
post-menopausal women on oestrogen-replacement therapy, and five post-menopausal women not on 
oestrogen-replacement therapy) (Penland, 1994, 1998). Studies began with a 14-day equilibration 
period, followed by a 63-day boron-depletion period, and ended with a 49-day boron-repletion period. 
The basal diet was supplemented with 3 mg boron/day during the equilibration and boron-repletion 
periods, and in one study the diets were also supplemented with 0.8 mg copper/day. Various tests of 
brain electrical activity and cognitive tasks were carried out at the end of these two periods. However, 
because the boron treatments were not randomised, it is not possible to distinguish between time and 
treatment effects. The Panel considers that no conclusions can be drawn from these two studies for 
the substantiation of the claim.  
One animal study investigated the effect of boron on measures of behaviour in rats. The Panel 
considers that evidence provided in animal studies is not sufficient to predict the occurrence of an 
effect of boron consumption on normal cognitive function in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of boron and contribution to normal cognitive function. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, boron, which is the subject of the health claims, is sufficiently 
characterised. 
Prevention and treatment of prostate cancer (ID 221) 
 The claimed effect is “prostate health”. The target population is assumed to be adult males. In 
the context of the references provided, it is assumed that the claim refers to prostate cancer 
prevention and treatment.  
 The claim does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
Maintenance of normal thyroid function (ID 222) 
 The claimed effect is “thyroid health”. The target population is assumed to be the general 
population. Maintenance of normal thyroid function is a beneficial physiological effect.  
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 A cause and effect relationship has not been established between the consumption of boron 
and maintenance of normal thyroid function. 
Contribution to normal cognitive function (ID 223) 
 The claimed effect is “mental health”. The target population is assumed to be the general 
population. Contribution to normal cognitive function is a beneficial physiological effect.  
 A cause and effect relationship has not been established between the consumption of boron 
and contribution to normal cognitive function. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1008, 
EFSA-Q-2008-1009, EFSA-Q-2008-1010). The scientific substantiation is based on the information 
provided by the Member States in the consolidated list of Article 13 health claims and references that 
EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES  
EFSA (European Food Safety Authority), 2004. Opinion of the Scientific Panel on Dietetic Products, 
Nutrition and Allergies on a request from the Commission related to the Tolerable Upper Intake 
Level of Boron. Request N° EFSA-Q-2003-018. The EFSA Journal 210, 1-9. 
Naghii MR, Wall PM and Samman S, 1996. The boron content of selected foods and the estimation of 
its daily intake among free-living subjects. Journal of the American College of Nutrition, 15, 614-
619. 
Penland JG, 1994. Dietary boron, brain function, and cognitive performance. Environmental Health 
Perspectives, 102 Suppl 7, 65-72. 
Penland JG, 1998. The importance of boron nutrition for brain and psychological function. Biological 
Trace Element Research, 66, 299-317. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
8
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
9
  
Foods are commonly involved in many different functions
10
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
8 OJ L12, 18/01/2007 
9 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
10 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Boron related health claims 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
Boron related health claims 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
Boron related health claims 
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APPENDIX C 
Table 1. Main entry health claims related to boron, including conditions of use from similar claims, as 
proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
221 Boron as boric acid Prostate health Boron is beneficial for 
prostate health. Boron helps to 
maintain a healthy prostate 
Conditions of use 
- 0.8 – 1,5 mg of boric acid. Must meet minimum requirements for use of the claim "source of 
[name of vitamin/s] and/or [name of mineral/s]" as per Annex to Regulation 1924/2006. 
ID Food or Food constituent Health Relationship Proposed wording 
222 Boron as boric acid Thyroid health Boron supports a healthy  
thyroid function. 
Boron is beneficial for the 
thyroid function. 
Conditions of use 
- 0.8 – 1,5 mg of boric acid. Must meet minimum requirements for use of the claim "source of 
[name of vitamin/s] and/or [name of mineral/s] " as per Annex to Regulation 1924/2006. 
ID Food or Food constituent Health Relationship Proposed wording 
223 Boron as boric acid  Mental health 
Clarification provided 
May help maintain normal 
brain function 
Boron supports the brain 
functioning 
Conditions of use 
- Food supplement with 3 mg of boron in the daily dose 
- 0.8 – 1,5 mg of boric acid ; Must meet minimum requirements for use of the claim "source of 
[name of vitamin/s] and/or [name of mineral/s]" as per Annex to Regulation 1924/2006 
 
